Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Buy” from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average rating of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

AMRX has been the topic of a number of analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and set a $22.00 target price on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. UBS Group lifted their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st.

Amneal Pharmaceuticals Trading Down 0.4%

Shares of Amneal Pharmaceuticals stock opened at $17.47 on Tuesday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm has a 50-day moving average of $17.71 and a 200-day moving average of $14.88. Amneal Pharmaceuticals has a 52-week low of $9.32 and a 52-week high of $19.26. The stock has a market cap of $5.58 billion, a PE ratio of 35.65 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.94 EPS for the current year.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares in the company, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AMRX. Louisiana State Employees Retirement System acquired a new position in shares of Amneal Pharmaceuticals during the first quarter worth $936,000. California State Teachers Retirement System increased its stake in shares of Amneal Pharmaceuticals by 37.6% in the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after buying an additional 56,588 shares during the period. HighTower Advisors LLC bought a new position in Amneal Pharmaceuticals during the 4th quarter worth approximately $1,121,000. Arkadios Wealth Advisors bought a new position in Amneal Pharmaceuticals during the first quarter worth $4,165,000. Finally, Renaissance Technologies LLC raised its position in shares of Amneal Pharmaceuticals by 1,586.8% in the 1st quarter. Renaissance Technologies LLC now owns 276,637 shares of the company’s stock worth $3,439,000 after acquiring an additional 260,237 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.